Vikram Kansra Selected Research

rolapitant

10/2019	Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.
3/2019	Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
1/2019	A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic.
1/2019	Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.
1/2019	Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects.
1/2019	An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant.
8/2018	Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects.
1/2018	Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
1/2018	Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
12/2017	Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open-Label Pivotal Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vikram Kansra Research Topics

Disease

10	Nausea 10/2019 - 09/2015
10	Vomiting 10/2019 - 09/2015
5	Neoplasms (Cancer) 01/2022 - 07/2012
3	Chronic Hepatitis C 01/2015 - 01/2013
3	Infections 01/2015 - 01/2013
2	Headache (Headaches) 01/2019 - 09/2015
1	Malignant Mesothelioma 01/2022
1	Dizziness (Lightheadedness) 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Ovarian Neoplasms (Ovarian Cancer) 01/2018
1	Constipation 09/2015
1	Hiccup (Hiccups) 09/2015
1	Neutropenia 09/2015
1	Dyspepsia (Indigestion) 09/2015
1	Chronic Hepatitis B 01/2015
1	Virus Diseases (Viral Diseases) 01/2013
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 07/2012
1	Multiple Myeloma 07/2012

Drug/Important Bio-Agent (IBA)

11	rolapitantIBA 10/2019 - 09/2015
9	Neurokinin-1 Receptor AntagonistsIBA 10/2019 - 12/2017
5	AntiemeticsIBA 03/2019 - 01/2018
4	Dexamethasone (Maxidex)FDA LinkGeneric 10/2019 - 07/2012
2	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 10/2019 - 09/2015
2	Pharmaceutical PreparationsIBA 01/2018 - 09/2015
2	peginterferon lambda-1aIBA 01/2015 - 01/2015
1	tazemetostatIBA 01/2022
1	Pemetrexed (MTA)FDA Link 01/2022
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 01/2019
1	Digoxin (Digitek)FDA LinkGeneric 01/2018
1	PlatinumIBA 01/2018
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2018
1	niraparibIBA 01/2018
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2018
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2018
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 09/2015
1	Cisplatin (Platino)FDA LinkGeneric 09/2015
1	Monoclonal AntibodiesIBA 01/2013
1	NivolumabIBA 01/2013
1	Antiviral Agents (Antivirals)IBA 01/2013
1	LigandsIBA 01/2013
1	beta-2 Adrenergic ReceptorsIBA 07/2012
1	GlucocorticoidsIBA 07/2012
1	Drug CombinationsIBA 07/2012
1	Adenosine (Adenocard)FDA LinkGeneric 07/2012
1	Bortezomib (Velcade)FDA Link 07/2012
1	Adrenergic Receptors (Adrenergic Receptor)IBA 07/2012
1	Melphalan (Alkeran)FDA LinkGeneric 07/2012

Therapy/Procedure

11	Drug Therapy (Chemotherapy) 10/2019 - 09/2015
2	Therapeutics 01/2022 - 07/2012
1	Aftercare (After-Treatment) 01/2022
1	Duration of Therapy 01/2015